Friday, Feb 2, 2024 · SEC filings

What the smart money revealed on Feb 2

Real insider buys25insiders · $6.52M
Real insider sales96insiders · $64.5M
Fund 13Fs filed—not loaded for this day
Activist 13Ds filed—not loaded for this day

1,192 insider filings came in. We hid 101 planned (10b5-1) sellers and 947 people whose filings were routine, like grants and tax withholding.

trending_up

BBX Capital (BBXIB) CEO and President Jarett Levan bought $4.6M

415,395 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Feb 2
$4.6M
trending_up

Rocky Mountain Chocolate Factory (RMCF) Director Jeffrey Geygan bought $875K

214,082 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 6 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 1 of 6 beat Traded Jan 31–Feb 1
$875K
trending_up

New Peoples Bankshares (NWPP) Director Blaine White bought $224K

89,557 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Feb 1
$224K
trending_up

Texas Capital Bancshares (TCBI) Director Robert Stallings bought $215K

Open-market buys of more than one share class. Not a grant or an option exercise. Their past buys: 7 of 9 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 7 of 9 beat Traded Jan 31–Feb 1
$215K
trending_down

Merck (MRK) EVP Steven Mizell sold $6.42M

Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 23,619 shares directly.

Real sale Form 4 Traded Feb 2
$6.42M
trending_down

Merck (MRK) EVP Jennifer Zachary sold $6.28M

Not marked as a planned 10b5-1 sale. Sold 63% of the shares they held directly. Still holds 29,058 shares.

Real sale Form 4 Sold 63% of stake Traded Feb 2
$6.28M
trending_down

BlackRock (BLK) CFO and Senior Managing Director Martin Small sold $5.53M

Not marked as a planned 10b5-1 sale. Sold 57% of the shares they held directly. Still holds 5,259 shares.

Real sale Form 4 Sold 57% of stake Traded Feb 2
$5.53M
Show 21 more real buys
INTC Intel · CEO Patrick Gelsinger · Traded Feb 1
$120K
SIGI Selective Insurance Group · Director Terrence Cavanaugh · Traded Feb 2
$98.5K
SXTP 60 Degrees Pharmaceuticals · Director Cheryl Xu · Traded Jan 31
$76K
MPB Mid Penn Bancorp · Director Matthew De Soto · Traded Jan 31–Feb 1
$50K
FRBBX Flat Rock Enhanced Income Fund · CFO Ryan Ripp · Traded Feb 1
$50K
RRBI Red River Bancshares · Director Teddy Price · Traded Feb 2
$49.2K
PKBK Parke Bancorp · President and CEO Vito Pantilione · Traded Feb 1
$28.8K
BUSE First Busey · Director Cassandra Sanford · Traded Feb 1
$22.9K
FMBM F&M Bank · CEO Aubrey Wilkerson · Traded Feb 1
$22.7K
COLB Columbia Banking System · Director Randal Lund · Traded Feb 1
$19.3K
FSBW FS Bancorp · Director Terri Degner · Traded Feb 1
$18K
TPL Texas Pacific Land · Director Murray Stahl · Traded Feb 1
$17.4K
SXTP 60 Degrees Pharmaceuticals · President and CEO Geoffrey Dow · Traded Jan 31
$9.87K
HNVR Hanover Bancorp · Director Robert Golden · Traded Jan 31
$9K
AGR Avangrid · Director Alan Solomont · Traded Feb 1
$5.01K
AVK Advent Convertible & Income Fund · Director Nancy Stuebe · Traded Feb 2
$4.74K
AIV Apartment Investment & Management · Director Deborah Smith · Traded Sep 30 · Filed late
$1K
FMBM F&M Bank · Evp/cfo Lisa Campbell · Traded Jan 31
$300
VANI Vivani Medical · Director Gregg Williams · Traded Jan 31
$101
RCG RENN Fund · President and CEO Murray Stahl · Traded Feb 1
$94
FMBM F&M Bank · EVP Kevin Russell · Traded Jan 31
$75
Show 93 more real sales
BLK BlackRock · Senior Managing Director J. Richard Kushel · Traded Feb 1–2
$5.26M
PCAR Paccar · CEO R. Preston Feight · Traded Feb 2
$2.82M
DAL Delta Air Lines · CEO Edward Bastian · Traded Feb 1
$2.82M
CL Colgate Palmolive · Grp Pres Panagiotis Tsourapas · Traded Jan 31
$2.57M
AXNX Axonics · CEO Raymond Cohen · Traded Jan 31
$2.38M
TEAM Atlassian · Co-CEO Scott Farquhar · Traded Feb 1
$2.1M
TDY Teledyne Technologies · Director Michael Smith · Traded Feb 2
$2.01M
BLK BlackRock · Senior Managing Director Mark Wiedman · Traded Feb 2
$1.97M
LRCX Lam Research · Senior Vice President Neil Fernandes · Traded Feb 1
$1.79M
CB Chubb · Chief Accounting Officer Annmarie Hagan · Traded Feb 1
$1.76M
TDY Teledyne Technologies · Director Kenneth Dahlberg · Traded Feb 2
$1.73M
NTRA Natera · CFO Michael Brophy · Traded Feb 1
$1.51M
EXPE Expedia Group · Director Dara Khosrowshahi · Traded Feb 1
$1.5M
RXST RxSight · Director William Link · Traded Feb 1
$1.4M
HCA HCA Healthcare · SVP-Payer Contracting and Align. Kathryn Torres · Traded Jan 31
$1.19M
IONS Ionis Pharmaceuticals · CEO Brett Monia · Traded Feb 2
$1.16M
AXNX Axonics · Chief Commercial Officer Alfred Ford Jr. · Traded Jan 31
$1.13M
BPOP Popular · Executive Vice President Lidio Soriano · Traded Jan 31
$1.12M
AXNX Axonics · EVP John Woock · Traded Jan 31
$1.08M
HCA HCA Healthcare · EVP and Chief Clinical Officer Michael Cuffe · Traded Jan 31
$982K
AXNX Axonics · Chief Medical Officer Karen Noblett · Traded Jan 31
$765K
CL Colgate Palmolive · EVP and Controller Gregory Malcolm · Traded Feb 1
$762K
MYFW First Western Financial · Chairman Scott Wylie · Traded Feb 1
$696K
OLN OLIN · VP and Pres Damian Gumpel · Traded Jan 31
$491K
PLXS Plexus · Exec. VP and CFO Patrick Jermain · Traded Jan 31
$453K
TEAM Atlassian · Co-CEO Michael Cannon-Brookes · Traded Feb 1
$413K
CMCO Columbus McKinnon · Sr VP Global Product Developm Lara Ramos · Traded Feb 1
$349K
TXN Texas Instruments · Director Mark Blinn · Traded Jan 31
$279K
AXNX Axonics · CFO Kari Keese · Traded Jan 31
$236K
CL Colgate Palmolive · Director C. Martin Harris · Traded Jan 31
$233K
GNTX Gentex · Director Richard Schaum · Traded Feb 1
$204K
TVTX Travere Therapeutics · CEO Eric Dube · Traded Feb 1
$166K
TDOC Teladoc Health · President Laizer Kornwasser · Traded Feb 2
$151K
MTB M&T Bank · Sr. Executive Vice President Doris Meister · Traded Feb 1
$132K
MASS 908 Devices · CFO Joseph Griffith IV · Traded Feb 1–2
$109K
IONS Ionis Pharmaceuticals · EVP Onaiza Cadoret-Manier · Traded Feb 2
$105K
IONS Ionis Pharmaceuticals · EVP Elizabeth Hougen · Traded Feb 2
$105K
IONS Ionis Pharmaceuticals · EVP Eugene Schneider · Traded Feb 2
$103K
IONS Ionis Pharmaceuticals · EVP Richard Geary · Traded Feb 2
$98.1K
IONS Ionis Pharmaceuticals · EVP CLO and General Counsel Patrick O'neil · Traded Feb 2
$97.4K
CBSH Commerce Bancshares · Director Benjamin Rassieur III · Traded Jan 29
$96.1K
IONS Ionis Pharmaceuticals · EVP C. Frank Bennett · Traded Feb 2
$91.8K
PLMR Palomar · CEO and Chairman Mac Armstrong · Traded Jan 31
$91.2K
OCUL Ocular Therapeutix · President and CEO Antony Mattessich · Traded Jan 31
$90.8K
TDOC Teladoc Health · COO Michael Waters · Traded Feb 2
$86.8K
TDOC Teladoc Health · Chief Medical Officer Vidya Raman-Tangella · Traded Feb 2
$79.2K
URGN UroGen Pharma · General Counsel Jason Smith · Traded Jan 31
$78.6K
AKBA Akebia Therapeutics · CEO and President John Butler · Traded Feb 1
$78.1K
DOCS Doximity · Director Kira Wampler · Traded Feb 1
$67.6K
MASS 908 Devices · President and CEO Kevin Knopp · Traded Feb 1
$63.5K
CALB California BanCorp · Sevp Scott Myers · Traded Feb 1
$63.3K
HTBK Heritage Commerce · Director Jack Conner · Traded Jan 31
$61.9K
AVIR Atea Pharmaceuticals · Chief Medical Officer Maria Horga · Traded Feb 1
$60.9K
AVIR Atea Pharmaceuticals · CFO Andrea Corcoran · Traded Feb 1
$60.8K
URGN UroGen Pharma · Chief Medical Officer Mark Schoenberg · Traded Jan 31
$59.6K
AVIR Atea Pharmaceuticals · Chief Development Officer Janet Hammond · Traded Feb 1
$53.9K
AVIR Atea Pharmaceuticals · EVP Wayne Foster · Traded Feb 1
$47.9K
AVIR Atea Pharmaceuticals · Chief Commercial Officer John Vavricka · Traded Feb 1
$45.4K
BL Blackline · Director Thomas Unterman · Traded Feb 1
$45K
SPFI South Plains Financial · Chairman and CEO Curtis Griffith · Traded Jan 31
$45K
TVTX Travere Therapeutics · SVP Elizabeth Reed · Traded Feb 1
$41.5K
TVTX Travere Therapeutics · Senior Vice President William Rote · Traded Feb 1
$41.5K
AKBA Akebia Therapeutics · SVP Steven Burke · Traded Feb 1
$40.8K
OCUL Ocular Therapeutix · Chief Medical Officer Rabia Ozden · Traded Jan 31
$38.4K
MASS 908 Devices · Chief Legal and Admin Officer Michael Turner · Traded Feb 1
$36.6K
TVTX Travere Therapeutics · Chief Commercial Officer Peter Heerma · Traded Feb 1
$35.8K
SAM Boston Beer · Chief People Officer Carolyn O'Boyle · Traded Feb 1
$35.8K
OCUL Ocular Therapeutix · General Counsel Philip Strassburger · Traded Jan 31
$33.8K
LICY Li-Cycle · CFO Debbie Simpson · Traded Feb 1
$33.6K
TVTX Travere Therapeutics · CFO Christopher Cline · Traded Feb 1
$32.6K
OCUL Ocular Therapeutix · CFO Donald Notman · Traded Jan 31
$31.8K
MASS 908 Devices · Chief Product Officer Christopher Brown · Traded Feb 1
$27.7K
OCUL Ocular Therapeutix · Chief Business Officer Christopher White · Traded Jan 31
$25.5K
VRSN Verisign · EVP- Engineering Danny McPherson · Traded Feb 1
$24.9K
TVTX Travere Therapeutics · SVP Sandra Calvin · Traded Feb 1
$24.1K
CKPT Checkpoint Therapeutics · CEO James Oliviero III · Traded Feb 1
$23.9K
PLMR Palomar · CFO T. Christopher Uchida · Traded Jan 31
$22.6K
PLMR Palomar · President Jon Christianson · Traded Jan 31
$21.1K
MTCH Match Group · Chief Bus. Affairs and Leg. Off. Jared Sine · Traded Feb 1
$19.4K
MIRM Mirum Pharmaceuticals · SVP Jolanda Howe · Traded Feb 2
$19.2K
TVTX Travere Therapeutics · Chief Medical Officer Jula Inrig · Traded Feb 1
$18.5K
PLMR Palomar · Chief Risk Officer Jonathan Knutzen · Traded Jan 31
$17.5K
TDOC Teladoc Health · Chief Accounting Officer Richard Napolitano · Traded Feb 2
$16.7K
PLMR Palomar · Chief Legal Officer Angela Grant · Traded Jan 31
$15.2K
PLMR Palomar · Chief People and Prod. Officer Michelle Johnson · Traded Jan 31
$14.8K
CKPT Checkpoint Therapeutics · CFO William Gray · Traded Feb 1
$8.02K
UNTY Unity Bancorp · President/CEO James Hughes · Traded Jan 31
$6.87K
LICY Li-Cycle · Executive Chairman Timothy Johnston · Traded Feb 1
$4.48K
LICY Li-Cycle · President and CEO Ajay Kochhar · Traded Feb 1
$4.48K
PWCM Lm Funding America · Vice President of Operations Ryan Duran · Traded Jan 31
$1.53K
LICY Li-Cycle · General Counsel and Corporate Secretary Carl DeLuca · Traded Feb 1
$1.38K
LICY Li-Cycle · Chief Technical Officer Christopher Biederman · Traded Feb 1
$1.15K
AXDX Accelerate Diagnostics · CEO Jack Phillips · Traded Feb 1
$642

13F season

Holdings as of Dec 31, 2023 are due Feb 14

49 funds have filed so far. 40 filed for the quarter before.

Biggest real insider buys, Jan 27–Feb 2

Open-market buys by officers and directors, filed in the 7 days up to Feb 2.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist